Investor Presentaiton

Investor presentation Full year 2018 Slide 76 The GLP-1 segment accounts for around 12% of total diabetes care market value in Region Europe European GLP-1 market VictozaⓇ Exenatide DKK billion Dulaglutide Other GLP-1 market value CAGR value¹: 20.8% 9876543216 0 Nov 2013 VictozaⓇ value market share in Region Europe Share of total diabetes care market GLP-1 value market share 10% 100% 8% 80% - 6% 60% 4% 40% 2% 20% 0% 0% Nov 2018 Nov 2013 Victoza® Exenatide Dulaglutide Other 54% 34% 10% 2% Nov 2018 1 CAGR for 5-year period Source: IQVIA monthly MAT Nov, 2018 value figures changing diabetes Source: IQVIA monthly MAT Nov, 2018 value figures novo nordisk

View entire presentation